SCAI COVID-19 Hospital Toolkit
With the aim of arming hospitals and healthcare centers with external communication materials focused on the critical importance of seeking medical attention when experiencing symptoms of heart attack and stroke, SCAI has developed a hospital toolkit complete with infographics, social media content, fact sheets, and other turnkey communications.
Help SCAI Advocate for You: Surveys Addressing the Impact of COVID-19 on Interventional Cardiology
SCAI has commissioned key task forces to study the impact of the COVID-19 pandemic on trainees, training programs, and Cath Lab operations and economics. Armed with these data, SCAI will be able to advocate on your behalf and develop vital resources for you and your patients. Please complete the surveys that are relevant to your role.
SCAI and CAIC Announce the Formation of the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI)
The Society for Cardiovascular Angiography and Interventions (SCAI) and the Canadian Association of Interventional Cardiology (CAIC) announce the formation of the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI). The study will be chaired by Tim Henry, MD (SCAI), and Payam Dehghani, MD (CAIC). Any COVID-19 positive patients or persons under investigation (PUI) with ST-Segment Elevation or new-onset left bundle branch block with a clinical correlate of myocardial ischemia (chest pain, dyspnea, cardiac arrest, hemodynamic instability) will be in enrolled. The data will be compared to an age and gender-matched control population from the existing Midwest STEMI Consortium which is a large (>15,000), prospective multi-center registry of consecutive STEMI patients. The NACMI registry has pending central IRB approval and will have an EKG and angiographic core lab. Interested sites can designate a local principal investigator and contact either SCAI PI Tim Henry (Tim.Henry@thechristhospital.com), CAIC PI Payam Dehghani (pdehghani@me.com) or the data coordinating center (santiago.garcia@allina.com or ross.garberich@allina.com) to obtain participating site information.
We believe that this registry has the potential to provide critically important time-sensitive data to inform the management and treatment guidelines applicable to COVID-19 patients.